Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists
- 1 September 2013
- journal article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 11 (9), 1627-1639
- https://doi.org/10.1111/jth.12318
Abstract
No abstract availableThis publication has 99 references indexed in Scilit:
- Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical ImportanceCurrent Pharmaceutical Design, 2012
- Platelet Function Testing in Atherothrombotic DiseaseCurrent Pharmaceutical Design, 2012
- Pharmacogenetics of the Antiplatelet Effect of AspirinCurrent Pharmaceutical Design, 2012
- Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?Journal of Thrombosis and Haemostasis, 2012
- Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active MetaboliteDrug Metabolism and Disposition, 2009
- Aspirin Dose for the Prevention of Cardiovascular DiseaseJAMA, 2007
- Genomic Medicine — A PrimerThe New England Journal of Medicine, 2002
- Genetic and Environmental Contributions to Platelet AggregationCirculation, 2001
- Identification and Biological Activity of the Active Metabolite of ClopidogrelThrombosis and Haemostasis, 2000
- A Polymorphism of a Platelet Glycoprotein Receptor as an Inherited Risk Factor for Coronary ThrombosisThe New England Journal of Medicine, 1996